Visante: Artificial Manufacturer Barriers to Competition Lead to High Insulin Prices
(Washington, D.C.) — A highly consolidated insulin market limits competition and allows dramatic price increases on new and existing brand-name products, according to a new Visante analysis: “Insulins: Managing Costs with Increasing Manufacturer Prices.” The Visante analysis finds that insulin list prices escalated